Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging

OBJECTIVE: The 2-year incidence of brain metastases (BrMs) in stage III non-small lung cell cancer (NSCLC) has been estimated to be around 30%. However, recent clinical trials have demonstrated considerably lower BrMs rates in this patient population. In this study, we aimed to review the real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhusaini, Saud, Lanman, Tyler A., Ko, Ryan B., Therkelsen, Kate E., Eyben, Rie Von, Diehn, Maximilian, Soltys, Scott G., Pollom, Erqi L., Chin, Alexander, Vitzthum, Lucas, Wakelee, Heather A., Padda, Sukhmani K., Ramchandran, Kavitha, Loo, Billy W., Neal, Joel W., Nagpal, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080021/
https://www.ncbi.nlm.nih.gov/pubmed/37035171
http://dx.doi.org/10.3389/fonc.2023.1139940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080021/
https://www.ncbi.nlm.nih.gov/pubmed/37035171
http://dx.doi.org/10.3389/fonc.2023.1139940

Ejemplares similares